Prolactinomas are the most common functional pituitary neuroendocrine tumors, accounting for nearly half of all ...
Prolactinomas are the most common hormone-secreting pituitary tumors, but their diagnosis and management can be challenging ...
On Wednesday, Defense Secretary Pete Hegseth made the startling announcement that the US military would begin requiring all ...
The defense secretary’s idea of administering testosterone therapy to members of the US Armed Forces reveals little ...
Vertex Pharmaceuticals Incorporated’s $10B Crinetics Pharmaceuticals, Inc. buy adds PALSONIFY & a Phase 3 CAH asset. Click for more on VRTZX and CRNX stock.
Vertex Pharma to buy Crinetics Pharmaceuticals for $10 billion: Boston Wednesday, July 8, 2026, 14:00 Hrs [IST] Vertex Pharmaceuticals Incorporated, a global biotechnology company ...
Vertex to acquire CRNX for $10B, adding approved rare disease drug Palsonify and late-stage pipeline assets to expand its endocrinology portfolio.
Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.
Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of ...
"The revelation was more than I could process.” ...
In a small cohort of patients with Cushing’s disease, most had their urinary free cortisol normalized after being ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results